A1 Journal article – refereed
Are Breast Cancer Nomograms Still Valid to Predict the Need for Axillary Dissection?
List of Authors: Madekivi Vilma, Karlsson Antti, Boström Pia, Salminen Eeva
Publisher: KARGER
Publication year: 2021
Journal: Oncology
Journal name in source: ONCOLOGY
Journal acronym: ONCOLOGY-BASEL
Number of pages: 5
ISSN: 0030-2414
eISSN: 1423-0232
DOI: http://dx.doi.org/10.1159/000514616
Abstract
Background: Nomograms can help in estimating the nodal status among clinically node-negative patients. Yet their validity in external cohorts over time is unknown. If the nodal stage can be estimated preoperatively, the need for axillary dissection can be decided.
Objectives: The aim of this study was to validate three existing nomograms predicting 4 or more axillary lymph node metastases.
Method: The risk for >= 4 lymph node metastases was calculated for n = 529 eligible breast cancer patients using the nomograms of Chagpar et al. [Ann Surg Oncol. 2007;14:670-7], Katz et al. [J Clin Oncol. 2008;26(13):2093-8], and Meretoja et al. [Breast Cancer Res Treat. 2013;138(3):817-27]. Discrimination and calibration were calculated for each nomogram to determine their validity.
Results: In this cohort, the AUC values for the Chagpar, Katz, and Meretoja models were 0.79 (95% CI 0.74-0.83), 0.87 (95% CI 0.83-0.91), and 0.82 (95% CI 0.76-0.86), respectively, showing good discrimination between patients with and without high nodal burdens.
Conclusion: This study presents support for the use of older breast cancer nomograms and confirms their current validity in an external population.
Background: Nomograms can help in estimating the nodal status among clinically node-negative patients. Yet their validity in external cohorts over time is unknown. If the nodal stage can be estimated preoperatively, the need for axillary dissection can be decided.
Objectives: The aim of this study was to validate three existing nomograms predicting 4 or more axillary lymph node metastases.
Method: The risk for >= 4 lymph node metastases was calculated for n = 529 eligible breast cancer patients using the nomograms of Chagpar et al. [Ann Surg Oncol. 2007;14:670-7], Katz et al. [J Clin Oncol. 2008;26(13):2093-8], and Meretoja et al. [Breast Cancer Res Treat. 2013;138(3):817-27]. Discrimination and calibration were calculated for each nomogram to determine their validity.
Results: In this cohort, the AUC values for the Chagpar, Katz, and Meretoja models were 0.79 (95% CI 0.74-0.83), 0.87 (95% CI 0.83-0.91), and 0.82 (95% CI 0.76-0.86), respectively, showing good discrimination between patients with and without high nodal burdens.
Conclusion: This study presents support for the use of older breast cancer nomograms and confirms their current validity in an external population.
UTU Research Portal